Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leptochloa fusca extract is an aqueous preparation derived from the shoot systems of the perennial grass *Leptochloa fusca*, commonly known as Sprangletop. It is characterized by a rich phytochemical profile containing phenols, flavonoids, alkaloids, tannins, saponins, and steroids. Preclinical research indicates that the extract possesses significant antioxidant, antiparasitic, antibacterial, and anticancer properties. Its anticancer mechanism of action involves the induction of apoptosis through the disruption of mitochondrial membrane potential, leading to cytochrome c release and subsequent caspase activation. In bacterial pathogens, it exhibits antibacterial effects by causing DNA damage and increasing plasma membrane permeability. The extract has shown in vitro efficacy against various parasites (e.g., *Plasmodium falciparum*), carcinogenic bacteria (e.g., *Helicobacter pylori*), and multiple cancer cell lines including gastric, pancreatic, and breast cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leptochloa fusca extract.